Published in Cancer Res on May 01, 2004
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer (2008) 2.63
The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle (2009) 2.62
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A (2006) 2.41
Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J (2009) 1.94
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg (2006) 1.82
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal (2008) 1.81
Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia (2004) 1.71
Distinct biological roles for the akt family in mammary tumor progression. Cancer Res (2010) 1.62
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov (2014) 1.58
A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet (2008) 1.57
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol (2011) 1.56
The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell (2010) 1.53
The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res (2008) 1.53
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res (2009) 1.53
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer (2010) 1.48
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol (2009) 1.40
Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia (2009) 1.32
Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol (2010) 1.31
Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul (2014) 1.27
Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway. Sci Signal (2011) 1.24
Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene (2010) 1.23
Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Breast Cancer Res (2010) 1.22
Early dissemination seeds metastasis in breast cancer. Nature (2016) 1.20
Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells. Cancer Res (2010) 1.20
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs (2010) 1.16
Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell (2012) 1.09
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res (2005) 1.08
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer (2010) 1.07
Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res (2009) 1.07
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol (2012) 1.07
mTOR signaling in tumorigenesis. Biochim Biophys Acta (2014) 1.06
Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res (2013) 1.06
Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol (2010) 1.05
PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov (2014) 1.03
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. Cancer Discov (2015) 1.02
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol (2012) 1.01
Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr (2011) 1.01
Achieving specificity in Akt signaling in cancer. Adv Biol Regul (2012) 0.97
The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. J Carcinog (2011) 0.97
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors. Cancer Res (2010) 0.92
Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene (2011) 0.92
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen (2013) 0.89
Akt2 regulates expression of the actin-bundling protein palladin. FEBS Lett (2010) 0.89
AKT/PKB Signaling: Navigating the Network. Cell (2017) 0.87
Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells. PLoS One (2013) 0.86
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res (2016) 0.86
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat (2011) 0.86
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov (2015) 0.85
Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res (2008) 0.85
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int J Oncol (2012) 0.84
Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway. J Biol Chem (2011) 0.83
Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications. J Proteome Res (2006) 0.83
Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy. Future Oncol (2010) 0.82
AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer (2016) 0.80
Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget (2016) 0.80
Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma. Oncotarget (2012) 0.80
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer. Mol Cancer Ther (2016) 0.80
Inhibition of breast cancer invasion by TIS21(/BTG2/Pc3)-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes. Oncogene (2015) 0.79
Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway. Endocrinology (2008) 0.79
When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells (2014) 0.78
Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach. Genome Biol (2015) 0.78
Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition? J Chem Biol (2012) 0.78
A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development. Oncogene (2015) 0.77
The roles of akt isoforms in the regulation of podosome formation in fibroblasts and extracellular matrix invasion. Cancers (Basel) (2015) 0.76
Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. Br J Cancer (2013) 0.76
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci Rep (2017) 0.75
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget (2016) 0.75
Expression, localization, and phosphorylation of Akt1 in benign and malignant thyroid lesions. Endocr Pathol (2011) 0.75
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep (2017) 0.75
Suppression of Akt1- β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis. Cancer Lett (2017) 0.75
Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep (2017) 0.75
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 8.61
Systematic discovery of in vivo phosphorylation networks. Cell (2007) 6.94
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell (2006) 4.48
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell (2004) 4.34
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A (2003) 3.61
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 2.90
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89
Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol (2006) 2.71
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A (2007) 2.64
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res (2005) 2.63
Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol (2010) 2.58
Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol (2002) 2.54
Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis (2005) 2.52
Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol (2002) 2.48
Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. J Virol (2008) 2.43
Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer (2007) 2.41
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol (2006) 2.37
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem (2004) 2.37
Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res (2002) 2.29
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res (2003) 2.11
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
Aqueous shunt devices compared with trabeculectomy with Mitomycin-C for children in the first two years of life. Am J Ophthalmol (2003) 1.99
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet (2007) 1.98
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
Genomic DNA functions as a universal external standard in quantitative real-time PCR. Nucleic Acids Res (2006) 1.85
Virus cell-to-cell transmission. J Virol (2010) 1.84
ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J (2008) 1.82
Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev (2006) 1.80
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle (2011) 1.79
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Mouse Piwi interactome identifies binding mechanism of Tdrkh Tudor domain to arginine methylated Miwi. Proc Natl Acad Sci U S A (2009) 1.73
Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem (2003) 1.72
Deciphering arginine methylation: Tudor tells the tale. Nat Rev Mol Cell Biol (2011) 1.69
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Distinct biological roles for the akt family in mammary tumor progression. Cancer Res (2010) 1.62
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release (2009) 1.60
Maternal dioxin exposure combined with a diet high in fat increases mammary cancer incidence in mice. Environ Health Perspect (2010) 1.60
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res (2008) 1.59
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression. Cancer Discov (2011) 1.57
The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res (2009) 1.56
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother (2013) 1.54
T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res (2008) 1.54
Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res (2007) 1.54
Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell (2003) 1.53
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res (2009) 1.53
SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res (2008) 1.52
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res (2011) 1.52
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res (2005) 1.50
The endoplasmic reticulum stress response is involved in apoptosis induced by aloe-emodin in HK-2 cells. Food Chem Toxicol (2011) 1.49
Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem (2008) 1.49
EMT tumorigenesis in the mouse mammary gland. Lab Invest (2007) 1.47
Genetically encoded fluorescent sensors for intracellular NADH detection. Cell Metab (2011) 1.47
A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2004) 1.47
Memo mediates ErbB2-driven cell motility. Nat Cell Biol (2004) 1.47
Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A (2002) 1.44
Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol (2003) 1.43
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res (2010) 1.43
Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene (2002) 1.43
Structural basis for recognition of arginine methylated Piwi proteins by the extended Tudor domain. Proc Natl Acad Sci U S A (2010) 1.40
ErbB2 is required for muscle spindle and myoblast cell survival. Mol Cell Biol (2002) 1.39
Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res (2006) 1.39
Gold-nanocrystal-enhanced bioluminescent nanocapsules. ACS Nano (2014) 1.39
Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene (2003) 1.37
In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A (2004) 1.37
Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol (2003) 1.36
Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest (2008) 1.36
Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene (2002) 1.36
Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol (2005) 1.34
Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther (2004) 1.33
From whence will they come? - A perspective on the acute shortage of pathologists in biomedical research. J Vet Diagn Invest (2007) 1.32
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev (2012) 1.32
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res (2005) 1.32